SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IMNR - Immune Response
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Walt who wrote (1387)7/6/1999 2:32:00 PM
From: Don Hurst  Read Replies (1) of 1510
 
Walt, thanks very much for posting the 8K report.

I, however, find this information to be somewhat confusing and perplexing.

Confusing because it says that in 435 participants there is no difference in viral load results between HAART only and HAART and Remune patients. Then they say that in the 250 patients there is "significant difference in viral load" for those who were taking Remune over those who were not. Presumably those who were not are the HAART only patients. Obviously my confusion is just due to limited intelligence.

Perplexing because if Remune, which I understand has very limited side effects, were so good at reducing viral loads, why is not the HIV positive community screaming and yelling for FDA approval after these long many years when the DSMB have essentially said to at least 2500 patients; forget it?

Regards,

Don
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News